Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OCS restructuring

This article was originally published in The Gray Sheet

Executive Summary

Topsiders from the office of compliance and surveillance in FDA's Center for Devices and Radiological Health formulate restructuring plan that calls for transfer of postmarket surveillance activities from OCS to CDRH's office of training and assistance. The plan has been forwarded to CDRH Director Bruce Burlington, who is expected to sign off on it during the week of March 22. The plan also would restructure OCS' remaining operations along product lines. Late last year, OCS management floated a restructuring proposal that would have kept PMS duties in OCS ("The Gray Sheet" Dec. 14, p. 2).



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts